Skip to main content

Market Overview

UPDATE: Oppenheimer Raises PT to $11 on KERYX Biopharmaceuticals; Zerenex Study Beats Expectations

Share:

Oppenheimer reiterated its Outperform rating on KERYX Biopharmaceuticals (NASDAQ: KERX) and raised the price target from $3.00 to $11.00.

Oppenheimer commented, "The results of the Long-Term Phase III study are significant and top-line data exceeded our expectations. Our prior base-case assumption was for minimal IV iron reduction and no reduction in ESA. The results showed a 52% decrease in cumulative IV iron use as well as a 27% decrease in median ESA intake. Both of these reductions of injectable drugs were statistically significant. As such, we believe that there is a good probability that these secondary endpoints will be included in Zerenex's final label."

KERYX Biopharmaceuticals closed at $6.06 on Monday.

Latest Ratings for KERX

DateFirmActionFromTo
Nov 2018Raymond JamesDowngradesOutperformMarket Perform
Aug 2018CitigroupMaintainsNeutralNeutral
Jun 2018Maxim GroupDowngradesBuyHold

View More Analyst Ratings for KERX
View the Latest Analyst Ratings

 

Related Articles (KERX)

View Comments and Join the Discussion!

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
NETIJefferiesMaintains22.0
ATUSB of A SecuritiesDowngrades38.0
CNIVertical ResearchUpgrades
LINVertical ResearchUpgrades330.0
SITEBerenbergUpgrades207.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com